We have investigated the potential use of ␤-conglutin protein isoforms from narrowleafed lupin (Lupinus angustifolius L.) as a diabetes treatment.
Introduction
Recently, the health beneficial effects of plant-derived compounds have been increasingly investigated [1] , including proteins from legume seeds [2] , as food supplements [3] . These studies showed the biological activities of some legume proteins and proteins from other plant species as modulators of chronic diseases [4, 5] . However, most of these studies did not investigate the molecular mechanisms underlying these positive health effects. Furthermore, most studies used whole seeds, where thousands of compounds would be present, and thereby not defining the exact molecule(s) that promote particular health effects such as reduction of body weight, food intake [6] , and a decrease in the LDL level in plasma [7] .
Considerable interest has been focused toward legume seed proteins [8] , especially those from lupins, a legume of the Fabaceae family. The seeds of the "Sweet Lupins" (Lupinus angustifolius or blue lupin, Lupinus albus or white lupin, and Lupinus luteus or yellow lupin) have low alkaloid content [9] , and are attracting attention because of their nutritional attributes [10] and potential for disease improvement [11] . These properties are associated with the seeds' high protein and dietary fiber content, which help reduce blood pressure and the risk of cardiovascular disease [12] , as well as impacting on the prevention and treatment of type 2 diabetes (T2D) [13] . The question that needs to be answered is which compound(s) among the lupin seed content mediates these effects.
Narrow-leafed lupin (NLL), L. angustifolius (L.), seeds are rich in proteins, which belong to four main families: ␣-, ␤-, ␥-, and ␦-conglutins [14] . Of these, the ␤-conglutins, a vicilin or 7S globulin, is the major seed storage protein in NLL and in Lupinus species [15] , which belong to the Cupin superfamily [16] , and mainly associated (as storage protein function) with plant physiological processes through the supply of amino acids during seedling germination [17] . NLL seed storage proteins are getting increased awareness and international recognition as a potential food for humans as its protein-rich seeds contain a large quantity of dietary fiber, are low in fat and starch, are gluten free, and have a very low glycemia index [18, 19] . Recently, seven genes coding for individual ␤-conglutins namely conglutin ␤1-conglutin ␤7 have been identified in NLL [14, 15; (http://www.lupinexpress.org)]. The ␤-conglutins are the most highly expressed conglutin family in NLL, and constitute 56% of the total conglutin transcript content in NLL seeds [15] . Despite of that, nothing is known so far about the potential and alternative functions that individual NLL ␤-conglutin proteins may exhibit in relationship to health benefits.
At present, T2D is one of the main global health concerns with its ensuing deleterious complications such as retinopathy, neuropathy, heart attack, and atherosclerotic vascular disease [20] . The aim of our study was to test the effects of different purified recombinant ␤-conglutin proteins on whole blood cultures from T2D patients and healthy control subjects.
Material and methods

Construction of expression plasmids
The expression system used for bacterial expression was a modified variant of a pET28a vector (Novagen) containing an N-terminal polyhistidine (6xHis) Tag. A pUC57 vector containing a synthetic gene encoding for each conglutin protein GenBank accession number HQ670409 (␤1), HQ670410 (␤2), HQ670411 (␤3), HQ670412 (␤4), and HQ670414 (␤6), connected by restriction enzyme linkers consisting of ccatgg (NcoI) and ctcgag (XhoI) sequences, were created synthetically by GenScript. The bacterial expression vectors pET28a(+)-␤-conglutin-6xHis-Tag for ␤1, ␤2, ␤3, ␤4, and ␤6 were obtained via digestion of respective pUC57-␤-conglutin construct using double NcoI and XhoI restriction enzymes digestion, followed by ligation of the ␤1-␤4 and ␤6 fragments into the pET28a(+) vector.
␤-Conglutin protein variants overexpression
All ␤-conglutin proteins were expressed in Rosetta TM 2(DE3) pLysS Singles TM Competent Cells (Novagen). Proteins expression was performed by using the autoinduction method [21] . Briefly, a colony of Escherichia coli containing the expression construct was isolated and grown for 20 h in ZY-medium plus kanamycin at 50 g/mL at 37ЊC and continuous shaking (200 rpm). The culture was diluted 1:150 in Studier medium and grown for a further 5 h until cell density reached 0.7 OD 600 nm, to subsequently inducing overexpression of the proteins by adjusting the temperature to 19ЊC for another 16 h. Cells were collected by centrifugation at 5000 × g at 4ЊC. Bacterial cell pellet was rinsed two times with PBS, pH 7.5, removing the supernatant and the cell pellet was flash frozen using liquid nitrogen. The bacterial cell pellet was stored at -80ЊC until further use.
Purification of recombinant conglutin ␤1, ␤2, ␤3, ␤4, and ␤6 proteins
Overall, protein purification from bacterial pellets was performed following company protocol recommendations (Qiagen) for His-tagged proteins. Briefly, the steps consisted of breaking cells, following by nickel affinity chromatography using Ni-NTA spin columns, and 6xHis-Tag at the C-terminal part of each ␤-conglutin protein. After elution of proteins from the column with an increasing imidazole concentration gradient (10-300 mM), 2.5 mL fractions were collected. Fractions containing protein were analyzed using SDS-PAGE and fractions showing a single band corresponding to the expected molecular weight were pooled, aliquoted, and flash frozen in liquid nitrogen and kept at -80ЊC until further uses. Purity of the protein samples resulted in >95%. Typical yields after nickel affinity chromatography were ß5-15 mg/mL.
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␤-Conglutin antibody production
A peptide, Nt -VDEGEGNYELVGIR -Ct, specific for the seven NLL ␤-conglutin proteins variants was synthesized (Agrisera, Sweden). This peptide was used to immunize rabbits and to produce polyclonal antiserum. The rabbit immune serum was affinity-purified against the same synthetic peptides (Agrisera).
Immunoprecipitation assays
Immunoprecipitation was performed using the Thermo Scientific Pierce (Rockford, IL, USA) co-immunoprecipitation Kit 26149 following the manufacturer's protocol. Briefly, the monoclonal anti-6xHis-Tag antibody (Sigma-Aldrich) was first immobilized using AminoLink Plus coupling resin. The resin was then washed and incubated with individual purified conglutin ␤1, ␤2, ␤3, ␤4, and ␤6 recombinant protein and human recombinant insulin (Sigma) for 4 h at 4ЊC. After incubation, the resin was washed and protein eluted using elution buffer. Negative controls were performed by immobilizing anti ␤-conglutin antibody (C1) or monoclonal anti6xHis-Tag antibody (C2) to AminoLink Plus coupling resin, and using human recombinant insulin without adding any of the purified recombinant ␤-conglutins in the incubation, and further elution step. Elution samples were analyzed by SDS-PAGE and stained with Coomassie blue, as well as by Western blotting using rabbit monoclonal anti-insulin (Abcam, Cambridge UK), and a horseradish peroxidase conjugated secondary goat-IgG antirabbit antibody. Chemiluminiscent detection was carried out as described below (Section 2.9). Results visualization and documentation were performed with a C-DiGit blot scanner (LI-COR, USA).
Participants' study
A total of 27 healthy control subjects and 31 diabetic patients were recruited for this study, and respective informed full consents were obtained from each participant. The subjects were unrelated and diagnosed at the coverage area of basic area "Pedro Martínez" (A.G.S. NorthEast Granada, Spain). Samples consisted of venous blood, which was collected from the cubital vein in 4-mL lithium-heparin tubes by well-trained authorized personal. All study procedures were performed in accordance with a protocol previously approved by the Ethics Committee of Basic Area "Pedro Martínez" (A.G.S. NorthEast Granada, Spain). All participants provided full written and informed consents for the procedures.
All experiments were performed in agreement to "The Principles of Good Laboratory Practice", developed in accordance with the OECD and adopted by the EU (Directive 2004/9/EC, and Directive 2004/10/EC).
All methods and experimental protocols included in Section 2 corresponding to the current study were approved by The Estación Experimental del Zaidín, Granada (Spain), the institution belonging to the Spanish National Research Council (CSIC), where all experimental procedures were performed. In addition, all methods and experimental protocols were also approved by the Research Ethics Committee of the Granada province, Andalusian Health System (Spain).
Whole blood culture
Venous blood was drawn into lithium-heparin tubes (BD Vacutainer System, Heidelberg, Germany) in the morning. Participants were fasted for 12 h before blood collection (fasting consisted of no food or drink intake but water). Within 3 h, whole unseparated blood was diluted 1:3 with DMEM and HEPES 4% (Invitrogen, Karlsruhe, Germany), and agitated gently in 50-mL tubes (Greiner Bio-One, Solingen, Germany); 1 mL aliquots were seeded per well of 24-well plates (Nunc, VWR International GmbH, Langenfeld, Germany) and cultured for 24 h at 37ЊC and an atmosphere of 5% CO 2 . The whole blood assay procedure was established from pilot studies with blood from four healthy subjects. All parameters for each subject including blood withdrawal were measured in one assay on the same plates in order to ensure intraindividual cross-comparison of results. From each blood drawing, we performed triplicate incubations with negative controls, and the separate purified ␤-conglutin (20 g/mL) or E. coli lipopolysaccharide (LPS, 5 pg/mL) and each ␤-conglutin protein in combination with LPS. Samples were incubated in triplicate with negative controls (PBS 25%; Sigma-Aldrich). The same lots of purified ␤-conglutin (␤1, ␤2, ␤3, ␤4, and ␤6), LPS, and PBS were used for all experiments. Blood cultures were removed from each well to be centrifuged at 700 × g for 5 min at 20ЊC, and supernatants were aliquoted and stored at -20ЊC until further analysis.
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by density-gradient centrifugation on Histopaque 1077 (Sigma, St. Louis, MO), washed three times in Hanks' balanced salt solution (Life Technologies, Grand Island, NY), and resuspended in complete medium including RPMI 1640 (Sigma) supplemented with penicillin, streptomycin, and L-glutamine (100 U/mL, 100 g/mL, and 2 mM) (Sigma). Total mRNA was isolated from culture supernatants by using the mRNeasy min kit (Qiagen, the Netherlands) and total mRNA was extracted from the cultured PBMCs with RNeasy mini kit 50 (Qiagen) according to the instructions of the manufacturer. First-strand complementary DNA (cDNA) was synthesized using High-Capacity cDNA Archive Kit (Applied Biosystems, Weiterstadt, Germany). For gene expression assays, cDNA was amplified using 7500 Fast RealTime PCR System (Applied Biosystems). TaqMan primers and probes were derived from the commercially available TaqMan Gene Expression Assays (GenBank accession no: NM_005544.2, Assay ID: Hs00178563_m1; GenBank accession no.: NM_001042.2, Assay ID: Hs00168966_m1; GenBank accession no.: AF049656.1, Assay ID: Hs01075529_m1 and GenBank R accession no.: NM_000576.2, Assay ID: Hs01555410_m1; Applied Biosystems). Relative changes in gene expression levels were determined using the 2 − ⌬⌬Ct method. The cycle number at which the transcripts were detectable (CT) was normalized to the cycle number of ␤-Actin (GenBank accession no.: NM_001101.3, Assay ID: Hs99999903_m1) detection, referred to as ⌬CT. PCR efficiency was determined by TaqMan analysis on a standard curve for targets and endogenous control amplifications, which were highly similar.
Relative messenge
Quantitative immunoblotting
The analyses were performed on culture supernatants obtained from whole blood culture. Total protein concentration was determined for each sample with the Bradford assay (Bio-Rad) using bovine serum albumin as a standard. Aliquots corresponding to 20 g of total proteins were heated to 95ЊC for 5 min with an equivalent volume of sample buffer, containing 2% SDS and 5% mercaptoethanol, bromophenol blue and 20% glycerol, and loaded onto 10% and 12% polyacrylamide gels for protein separation. Proteins separated by SDS-PAGE were electrotransferred to PVDF membranes and probed with appropriate antibodies. Membranes were blocked for 1 h at 37ЊC in a blocking solution containing 3% BSA, 0.05% Tween-20, and PBS (pH 7.4) and incubated overnight at 4ЊC with primary antibodies in the blocking solution. These primary antibodies consisted of anti-(IRS-1 (107-185 kDa), PI3-kinase (p85) (85 kDa), GLUT-4 (50-60 kDa), and protein kinase B (AKT) (60 kDa), which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and the antibodies against iNOS (130 kDa) and IL-1␤ (17 kDa) were purchased from Abcam. Membranes were rinsed three times with washing solution (0.05% Tween-20 in PBS) for 10 min each, followed by incubation for 1 h at room temperature in a 1:5000 dilution of goat anti-rabbit IgG-HRP, purchased from Santa Cruz Biotechnology, with 3% BSA in PBS. The membranes were then washed three times for 10 min each in the same washing solution. Chemiluminiscent detection was Figure 1 . Purification of conglutin ␤1, ␤2, ␤3, ␤4, and ␤6. The Coomassie-stained shows the five purified ␤-conglutin proteins. Immunoblotting shows the five purified ␤-conglutin proteins identified by the anti-␤-conglutin antibody (asterisks). MW, molecular weight standard (kDa).
carried out with the Immun-StarTM WesternCTM Chemiluminescence Kit (cat# 170-5070; Bio-Rad) according to the manufacturer´s instructions. Visualization and documentation of the results was performed with a C-DiGit blot scanner (LI-COR, USA). Quantitative (densitometry) analysis of protein bands was performed using ImageJ v1.47 (Bio-Rad).
Statistical analysis
Data are expressed as means ± SEM of six patients for group. Two-tailed Student's t-test was used to compare between two groups. One-way analysis of variance followed by Dunnett's test was used to compare among three or more study groups. p < 0.05 is regarded as statistically significant.
Results
Purification of ␤-conglutin proteins and immune precipitation assay
The SDS-PAGE analyses indicated a single protein band of approximately 65 kDa ( Fig. 1) . Recombinant ␤-conglutins6xHis-Tagged were obtained at high purity level (>95%), and a concentration between 5 and 15 mg/mL (Fig. 1) . Analysis by immunoblotting using anti-␤-conglutin protein antibody produced in the current study confirmed the identity of the recombinant protein (asterisks, Fig. 1 ). We further investigated whether human recombinant insulin was able to interact with the ␤-conglutin proteins (␤1, ␤2, ␤3, ␤4, or ␤6) by immunoprecipitation experiments. Precipitated species were detected by coomassie staining ( Fig. 2A) , and confirmation of the presence of insulin in the eluated samples was performed by immunoblotting using an anti-insulin antibody (Abcam) (Fig. 2B) . Insulin was found at relatively high quantity in the eluate samples when incubated with purified conglutin ␤1, ␤3, and ␤6 (Fig. 2) , when compared to controls.
Participant information
The clinical parameters of the population studied are summarized in Table 1 . Healthy control subjects and patients with T2D showed significant differences for age and BMI, as expected. There were significant differences between study groups in the levels of fasting glycemia (p < 0.001), blood pressure (p < 0.03), heart rate (p < 0.001), and HbA1c (p < 0.001).
Challenging assays using PHA, LPS, and PMA + IO exhibited comparable values
We investigated whether incubation with PHA (phytohaemagglutinin), LPS, and PMA + IO (phorbol 12-myristate 13-acetate + ionomycin), respectively, had potential effects on the release of cytokines from whole blood samples. Challenging with PHA, LPS, or PMA + IO induce a potent stimulus of spontaneous cytokine IL-1␤ and iNOS production in whole blood cultures. The mean concentration values of IL-1␤ in culture supernatants of healthy control subjects after 24 h after incubation with PHA, LPS, or PMA + IO are shown in Fig. 3 .
We evaluated ex vivo IL-1␤ production with these three stimuli. Because of this the patterns of production were similar in all subjects tested leading to similar concentrations of IL-1␤, a whole blood culture system with LPS appeared to be most suitable to assess in our study (see exemplary for IL-1␤, Supporting Information Fig. 1 ).
Differential expression of genes related to the insulin molecular signaling pathway
We assessed whether the effect of each purified ␤-conglutin protein (␤1-␤4 and ␤6) on blood culture of T2D and controls (C) was related to the activation of the insulin signaling pathway. Expression levels of the IRS-1 gene were significantly lower in T2D patients (-75%, -75%, -81%, -91%, and -74% (Fig. 3A ) when compared to C in all experimental groups. Interestingly, 24 h after challenging using ␤1, ␤3, and ␤6, mRNA levels of the IRS-1 gene in T2D patients experienced a significant increase (+244%, +347%, and +280% versus T2D patients (Fig. 3A) . No differences were observed using ␤2-or ␤4-conglutin for challenge assays when compared to T2D (Fig. 3A) . After LPS challenge, we found significantly stimulated IRS-1 gene expression in T2D patients in all the experimental groups (+548%, +678%, +412%, +720%, and +710% versus T2D (Fig. 3A) . Challenge experiments using LPS + ␤2 and LPS + ␤4 enhanced mRNA expression of IRS-1 (+531%, and +620% versus T2D (Fig. 3A) . On the other hand, a significant reduction was found for challenges using LPS + ␤1, LPS + ␤3, and LPS + ␤6 (+85%, +128%, and +146% versus T2D (Fig. 3A) . Interestingly, challenge assays using ␤1, ␤3 and ␤6 significantly stimulated the expression of the IRS-1 gene in C subjects (+111%, +238%, and +116% (Fig. 3B) , and no significant differences were found in the expression levels of mRNA of the IRS-1 gene with ␤2 and ␤4 challenges versus C (Fig. 3B) . The mRNA expression levels of the IRS-1 gene were upregulated in LPS challenging assays (+497%, +333%, +601%, +636%, and +411%) in all experimental groups (Fig.  3B ). In addition, mRNA expression levels of the IRS-1 gene for challenges using LPS+␤2 and LPS+␤4 caused a significant induction (+326% and +534% versus C (Fig. 3B) when compared to LPS + ␤1, LPS + ␤3, and LPS + ␤6 (+63%, +20%, and +45%), in which mRNA levels also were partially increased when compared to control (Fig. 3B) .
Protein level of IRS-1 and P85 (mitogen-activated protein kinase) in culture supernatants were significantly reduced in T2D (IRS-1: -55%, -74%, -67%, and -87%; and p85: -72%, -69%, -58%, -46%, and -70%) in comparison to C in all experimental groups (Supporting Information Figs.  2A and 3A) . Noteworthy, challenges using ␤1, ␤3, and ␤6 showed that IRS-1 and p85 protein levels were significantly higher in plasma of diabetic patients (IRS-1: +187%, +299%, and +229% (Supporting Information Fig. 2A) ; p85: +337%, +356%, and +417% (Supporting Information Fig. 3A ) when compared to T2D. No significant changes were found with ␤2 and ␤4 when compared to T2D (Supporting Information Figs. 2A and 3A) .
Furthermore, a significant increase in IRS-1 and p85 protein levels was found for all different experimental groups using LPS in T2D subjects [IRS-1: +498%, +427%, +366%, 364%, and +385% (Supporting Information Fig. 2A ) versus T2D; p85: +495%, +392%, +166%, +392%, and +334% (Supporting Information Fig. 2A) versus T2D ). In addition, IRS-1 and p85 protein expression levels exhibited an increase in challenges using LPS + ␤2 and LPS + ␤4 (IRS-1: +517% and +412% (Supporting Information Fig. 1A ) versus T2D; p85: +412% and +357% (Supporting Information Fig. 3A ) versus T2D) compared to LPS + ␤1, LPS + ␤3, and LPS + ␤6 (IRS-1: +116%, +174%, and +187%; p85: +170%,+145%, and +105% versus T2D) in blood cultures of T2D subjects (Supporting Information Figs. 2A and 3A) .
A statistically significant increase in plasma IRS-1 and p85 proteins was observed in challenge assays using LPS in controls for all experimental groups (IRS-1: +254%, +332%, +432%, +332%, and +443% versus C (Supporting Information Fig. 2B) ; p85: +154%, +298%, +121%, +215%, and +254% versus C (Supporting Information Fig. 3B) .
We also found an increase in IRS-1 and p85 proteins levels using ␤1, ␤3, and ␤6 (IRS-1: +345%, +467%, and +413% (Supporting Information Fig. 2B ); and p85: +275%, +276%, and +312% (Supporting Information Fig. 3B ) when compared to controls. No differences were found in the protein expression levels of IRS-1 and p85 when challenges were performed using ␤2 and ␤4 in control subjects (Supporting Information Figs. 2B and 3B ). 
␤-Conglutin challenges result in a differential expression of genes related to glucose transport pathway
We also examined whether challenges with particular ␤-conglutins proteins would trigger the activation of the glucose transport pathway by quantification of the expression levels of GLUT-4 gene. T2D exhibited a significant reduction in the mRNA levels of GLUT-4 (-69%, -65%, -79%, -33%, and -80% (Fig. 3C ) versus samples from healthy control subjects. The reduced expression of GLUT-4 in the T2D group was clearly restored under ␤1, ␤3, and ␤6 challenges as illustrated in Fig. 3C (+428%, +430%, and +230% versus C). ␤2 or ␤4 caused no changes in the levels of mRNA of GLUT-4 when compared to T2D (Fig. 3C) . Stimulation with LPS exerted a significant increase in the expression of GLUT-4 in all the experimental groups (+428%, +182%, +428%, +430%, and +230% (Fig. 3C) . Furthermore, GLUT-4 mRNA expression levels were increased after using LPS + ␤2 and LPS + ␤4 in challenge assays (+243% and +648% (Fig. 3C) . No significative changes were noticed using LPS + ␤1, LPS + ␤3, or LPS + ␤6 [+135%, +143%, and +101% versus T2D (Fig. 3C) . However, LPS + ␤1, LPS + ␤3, and LPS + ␤6 showed recovery values of GLUT-4 mRNA expression levels when compared to LPS + ␤2 and LPS + ␤4 in challenge assays.
Protein expression levels of GLUT-4 and the insulindependent kinase AKT protein were decreased in T2D versus C group (GLUT-4: -77%, -57%, -88%, and -87% (Supporting Information Fig. 4A) ; AKT: -82%, -75%, -73%, -63%, and -67% (Supporting Information Fig. 5A ). Interestingly, this effect was reversed using ␤1, ␤3, and ␤6 in the challenge assays (GLUT-4: +342%, +386%, and +318% (Supporting Information Fig. 4A ) versus T2D; AKT: +396%, +385%, and +103% (Supporting Information Fig. 5A ) versus T2D). No significant effect was found with ␤2-or ␤4-conglutins when compared to C.
In addition, Supporting Information Figs. 4A and 5A also show a significant enhancement of GLUT-4 and AKT in LPS challenges for all the experimental groups (GLUT-4: +500%, +380%, +364%, +298%, and +341% versus T2D; AKT: +420%, +320%, +440%, +450%, and +445% versus T2D). However, T2D group showed higher levels of GLUT-4 and AKT protein expression in challenges with LPS + ␤2 (+400% and +394% versus T2D (Supporting Information Fig. 4A ) and LPS + ␤4 (+264% and +320% versus T2D (Supporting Information Fig. 5A ) compared to LPS + ␤1, LPS + ␤3, and LPS + ␤6 (GLUT-4: +175%, +175%, and +173% (Supporting Information Fig. 4A) ; IRS-1: +103%, +100%, and +83% (Supporting Information Fig. 5A ). In addition, challenge using LPS promoted significant increases in protein levels for GLUT-4 and AKT in control subjects (GLUT-4: +332%,+323%,+312%, +225%, and +276% (Supporting Information Fig. 4B) ; AKT: +165%, +154%, +184%, +112%, and +121% (Supporting Information Fig. 5B ), as well as in LPS + ␤2 and LPS + ␤4 challenges (+174% and +176% (Supporting Information Fig. 4B ) versus C; +134% and +144% (Supporting Information Fig. 5B) versus C) . A more moderate increase was found for challenges using LPS + ␤1, LPS + ␤3, and LPS + ␤6 (+54%, +54%, and +38% (Supporting Information Fig. 4B) ; +65%, +75%, and +46% (Supporting Information Fig. 5B ). Blood culture of control subjects challenged with ␤1, ␤3, and ␤6 significantly increased protein levels of GLUT-4 and AKT (GLUT: +365%, +326%, and +323% (Supporting Information Fig. 4B ) versus C; AKT: +294%, +299%, and +298% (Supporting Information Fig.  5B ) versus C). No changes were found when using ␤2 and ␤4 in challenge assays.
Variation in genes expression related to the insulin pathway in PBMCs isolated from blood of T2D subjects
IRS-1 and GLUT-4 were significantly reduced in T2D subjects when compared to control (IRS-1: -85%, -90%, -77%, -69%, and -69% (Fig. 5A) ; GLUT-4: -75%, -80%, -67%, -99%, and -89% (Fig. 5C ).
Therefore, challenge assays using ␤1, ␤3, and ␤6 raised the levels of IRS-1 and GLUT-4 mRNA in PBMC of T2D subjects (IRS-1: +230%, +210%, and +238% (Fig. 5A) ; GLUT-4: +301%, +298%, and +259% (Fig. 5C ).
␤-Conglutins affect the expression levels of inflammation-related genes important in T2D subjects
T2D is characterized by impaired insulin secretion and/or insulin sensitivity [22] , and sustained by chronic subclinical inflammation. In order to investigate the possible potential anti-inflammatory effects of purified ␤-conglutin proteins, we assessed the expression levels of iNOS and the proinflammatory cytokine IL-1␤. iNOS mRNA and protein levels were substantially increased in T2D in all experimental groups when compared to control (+642%, +603%, +735% +779%, and +855% (Fig.  4A) . ␤1, ␤3, and ␤6 significantly suppressed iNOS mRNA expression and protein levels in T2D (-610%, -735%, -713% (Fig. 4A) versus T2D) . In contrast, iNOS mRNA and protein levels remained significantly high (+284% and +130% (Supporting Information Fig. 6A ) versus T2D) when ␤2 and ␤4 were used in challenge assays. We also found iNOS mRNA and protein levels significantly increased in LPS + ␤2 and LPS + ␤4 challenges (+230% and +260 (Fig. 4A ) versus T2D; +87% and +15% (Supporting Information Fig. 6A ) versus T2D), while LPS + ␤1, LPS + ␤3, and LPS + ␤6 challenges resulted in a substantial reduction in the mRNA and proteins levels (-512%, -625%, and -641% (Fig. 4A) versus C; -510%, -548%, and -409% (Supporting Information (9 of 13) 1600819 ␤1, ␤3, and ␤6 did not alter mRNA and protein expression levels of iNOS in control subjects (Fig. 4C) . However, mRNA and protein levels of iNOS were significantly increased using ␤2 (+734% and +265% (Fig. 4C) versus C) and ␤4 (+938% and +206% (Fig. 4C) versus C) .
In this regard, gene expression and protein levels of IL-1␤ showed a similar pattern to iNOS ( Fig. 4C and D; and Supporting Information Fig. 7A and B) . Figure 4B shows a significant increase in mRNA expression and protein levels of IL-1␤ in T2D subjects in all the experimental groups (+642%,+603%, +735% +776%, and +755% (Fig. 4B) ; and +338%,+245%, +237% +227%, and +320% (Supporting Information Fig. 7A) . Interestingly, this effect was reduced after 24 h of incubation with ␤1, ␤3, and ␤6 (-610%, -735%, and -713% (Fig. 4B ) versus T2D; -310%, -202%, and -67% (Supporting Information Fig. 7A ) versus T2D). In addition, the mRNA expression level and protein quantity of IL-1␤ were significantly induced in LPS challenge assays in all experimental groups (+1252%, +1174%, +1134%, +1222%, and +1134% (Fig. 4D ) versus C), and (+238%, +245%, +367%, +387%, and +390% (Supporting Information Fig. 7B ) versus C). LPS + ␤2 and LPS + ␤4 challenges significantly increased the IL-1␤ levels of both mRNA and protein (+817% and +554% versus C (Fig. 4D) ; +265% and +376 (Supporting Information Fig. 7B) versus C) . No differences in IL-1␤ cytokine levels were found when challenges were performed with LPS + ␤2 and LPS + ␤4 in comparison to the LPS group or the T2D group. Nevertheless, a moderate induction was found after LPS + ␤1, LPS + ␤3, and LPS + ␤6 challenge assays when compared to LPS + ␤2 and LPS + ␤4 challenges in the T2D subject groups.
Inflammation-related genes response in PBMCs of T2D patients
Levels of iNOS and pro-inflammatory cytokine IL-1␤ mRNA were significantly higher in PBMC isolated from T2D (iNOS: +389%, +567%, +428%, +711%, and +698% (Fig. 5B) ; IL-1␤: +438%, +693%, +740% +850%, and +439% (Fig. 5D ) when compared to C. This induction was notably suppressed after 24 h of challenge with ␤1, ␤3, and ␤6 (-391%, -390%, and -377% (Fig. 5B) ; and -475%, -480%, and -467% (Fig.  5D ), whereas levels of iNOS and pro-inflammatory mediator IL-1␤ remained significantly high after ␤2 and ␤4 challenges in PBMC from T2D subjects ( Fig. 5B and D) .
␤-Conglutin pool affects the expression levels of insulin pathway and inflammation-related genes in PBMCs of T2D patients
In order to prove the join effect of the purified ␤-conglutins proteins in our study, challenging assays were performed using all individual ␤-conglutin isoform proteins together (␤1 + ␤3 + ␤6 + ␤2 + ␤4) in T2D patients and measured variations of IRS-1, GLUT-4, iNOS, and IL-1␤ levels through qRT-PCR. IRS-1 and GLUT-4 were significantly reduced in T2D patients when compared to C (-71% (Supporting Information Fig. 8A ), and -82% (Supporting Information  Fig. 8B ). Furthermore, challenging assays using ␤-conglutin pool caused the activation of mRNA synthesis levels of IRS-1 and GLUT-4 in stimulated PBMC of T2D (+398% (Supporting Information Fig. 8A ), and +438 (Supporting Information  Fig. 8B ). iNOS and IL-1␤ mRNA levels were significantly high in PBMC from T2D (+689% (Supporting Information  Fig. 8C ), and +711% (Supporting Information Fig. 8D ) when compared to C. Interestingly, challenge using ␤-conglutin pool suppressed the induction levels of iNOS and proinflammatory mediator IL-1␤ in T2D patients (-748% (Supporting Information Fig. 8C ), and -739% (Supporting Information Fig. 8D ), respectively).
Discussion
Finding an effective and natural alternative antidiabetic agent would be of enormous interest and importance for the prevention and treatment of T2D worldwide [23] .
Various bioactive (nutraceutical) properties of L. albus or white lupin seed compounds have been reported such as lowering plasma cholesterol and triacylglycerol concentrations in hypercholesterolemic animal models [24] .
Postprandial experiments have shown that healthy subjects that have consumed bread added with lupin flour [25, 26] or kernel fiber [27] had decreased levels of glucose, insulin, and satiety responses compared with those control subjects consuming regular white bread. Therefore, when lupin was compared to soy, postprandial glycemic lowering response for bread consumption was more efficient for lupin than soy in diabetic subject [28] . In addition, a basic globulin protein (␥-conglutin family) isolated from L. albus seeds have shown that it reduces the plasma glucose levels in rats in a dosedependent manner [29] , as well as glucose and insulin blood in rats treated with a hyperglycemic diet [30] .
In the present study, we have investigated the role of the L. angustifolius major seed protein, ␤-conglutin/vicilin proteins family, as a diabetes treatment. We have evaluated through challenge assays whether purified ␤-conglutin proteins of NLL are able to activate the intrinsic tyrosine kinases, triggering cell-signaling responses, commonly shared among the insulin signaling molecular cascade, i.e. IRS-1 pathway. Tyrosine phosphorylation of the IRS-1 protein allows its functional interaction with the regulatory subunit of PI3-K protein. This, in turn, activates PI3-K to a functional protein, necessary for insulin signaling for glucose transport [31] .
Outcomes showed that whole blood culture challenges using purified ␤1, ␤3, and ␤6 promote the activation of the intracellular IRS-1/PI3-kinase pathway eventually involved in glucose homeostasis and protein synthesis stimulation in T2D patients in comparison to control T2D subjects. Moreover, purified ␤1, ␤3, and ␤6 proteins were able to stimulate IRS-1 ( Fig. 3 and Supporting Information Fig. 2 ) and P85 (Supporting Information Fig. 3 ), increasing their protein levels in control (healthy) subjects.
The mechanism by which activation of PI3-K through tyrresidue phosphorylation [31, 32] induces GLUT-4 translocation and increases glucose uptake by the cells has not been defined. A downstream effector of PI3-K protein (serinethreonine kinase-AKT) may also play a fundamental role in insulin's effects and glucose transport [33] ; however, the role of this kinase in glucose transport is controversial [34] . In this regard, 24 h of challenge assays using ␤1, ␤3, and ␤6 resulted in the upregulation of mRNA and an increase in protein levels of GLUT-4 and AKT in plasma of T2D subjects. In contrast, GLUT-4 and AKT remained unaltered when ␤2 and ␤4 were used in the challenge assays. Since recombinant human insulin has been shown in the current study to have a preference for binding to ␤1, ␤3, and ␤6, these proteins may be involved somehow in the variations of mRNA and protein levels of some of the above markers of the insulin pathway.
Taking all these results into consideration, and to the best of our knowledge, we propose for the first time that ␤1, ␤3, and ␤6 proteins have the ability to regulate the level of mRNA and protein synthesis of crucial genes involved in the insulin molecular signaling pathway, thereby modulating the activation and response of these regulatory genes leading to variation in insulin-mediated plasma glucose levels.
The administration of LPS has been previously applied as an experimental model to mimic some of the clinical findings of human T2D [35] . The kind of vicious stimulus, at the same time, leads to severe metabolic disorder [36] . Thus, endotoxemia would induce acute insulin resistance and adipose inflammation, characteristic of that observed chronically in metabolic syndrome and diabetes.
LPS triggers inflammation, which is associated with marked changes in glucose metabolism; thus, LPS-induced glucose metabolism disorder is recently getting more attention as a prominent pathological problem [37] . Indeed, LPS challenge assays performed in the current study resulted in a significant activation of protein levels and gene transcriptional expression of kinases, IRS-1 and GLUT-4 in all different experimental groups. Mediators of the inflammatory response have been shown to impair insulin signaling to muscles and blood flow [38] . However, little work has been done in order to examine functional interaction among these particular factors. Fan et al. [36] found that LPS leads to whole body insulin resistance in rats and impaired insulin signaling. A recent in vivo study using a hyperinsulinemic-euglycemic clamp in mice was unable to detect impairment in insulin action following an LPS injection [39] . Therefore, it is unclear how much of the impairments are signaling mediated.
While a number of factors can contribute to inhibition of insulin-stimulated glucose uptake by cells in the presence of an LPS challenge, there is scarce information about the relationship between the LPS-induced inflammatory response, insulin signaling, and decreased muscle glucose delivery [40] .
Importantly, when LPS and purified ␤-conglutin proteins were jointly added to the challenge assays, we found that LPS + ␤1, LPS + ␤3, and LPS + ␤6 significantly reduced the level of intracellular mRNA for these genes belonging to the intracellular insulin signaling molecular pathway in comparison to LPS challenge in T2D and in control (healthy) subjects; conversely no effects were found in challenge assays using LPS + ␤2 and LPS + ␤4, results that might be associated with the antioxidant properties and anti-inflammatory effects of ␤1, ␤3, and ␤6. To the best of our knowledge, this is the first time on the ability of specific NLL ␤-conglutin proteins to modulate the chronic subclinical inflammation caused by T2D.
At present, T2D is associated with oxidative stress and chronic inflammation by increasing the formation of reactive oxygen species and causing reduction in the antioxidant levels [41] . Therefore, inhibitors of the pro-inflammatory cytokines have been considered as candidates for anti-inflammatory drugs [42] . This type of activation is associated with an elevated production of pro-inflammatory cytokines, such as tumor necrosis factor, IL-6, and IL-1, ROS (reactive oxygen species), and nitrogen intermediates such as the inducible isoform of nitric oxide iNOS [43] .
The increase in the incidence of inflammation-related disorders has led to the search for active biopeptides derived from plant proteins with anti-inflammatory properties [1] . In the present study, we investigated the potential anti-inflammatory activity of five purified NLL ␤-conglutin proteins. We observed a markedly pronounced activation of iNOS, an IL-1␤, in culture supernatants of T2D patients. Notably, IL-1␤ and iNOS showed a significant inhibition after 24 h of incubation with either ␤1-, ␤3-, or ␤6-conglutin proteins in T2D patients. Gene expression of IL-1␤ and iNOS showed a similar pattern in PBMC in accordance to the results observed in blood culture supernatants of T2D patients.
Therefore, we analyzed the effects of each purified ␤-conglutin protein in plasma, with the presence of stimuli of the innate immune system (endotoxin LPS). In our study, LPS represents a strong immunostimulatory signal that induces a systemic inflammatory response with increases in pro-inflammatory cytokines such as IL-1␤ and iNOS in all experimental groups (T2D and control) [44] . In parallel experiments, we also found that LPS + ␤1, LPS + ␤3, and LPS + ␤6 challenge assays strongly reduced the mRNA expression of IL-1␤ when compared to LPS alone in T2D subjects. On the other hand, no significant differences were observed between LPS + ␤2 and LPS + ␤4 challenges when compared to LPS. Previous studies using dietary proteins from animal and plant sources have demonstrated specific effects going beyond merely nutrient supply [1] . However, our results indicate for the first time that ␤1, ␤3, and ␤6 trigger the release of pro-inflammatory capacity of cells by diminishing IL-1␤ and iNOS mRNA expression and protein levels, leading to (11 of 13) 1600819 amelioration of the inflammatory process associated with T2D in whole blood cultures.
Most importantly, our study provides novel and interesting information, particularly on how ␤1, ␤3, and ␤6 proteins from NLL have a completely different phenotype at the gene expression level of T2D patients in comparison to ␤2 and ␤4, through their ability to modulate the intracellular IRS-1/PI3-kinase/AKT7-GLUT-4 signaling pathway, that are eventually involved in protein synthesis stimulation, as well as their antioxidant and anti-inflammatory nature.
An initial study has showed the structural differences of the seven ␤-conglutin proteins modeled structures [45] , where the sequences identity ranged from 73 to 99% (Supporting information Fig. 9) . This relatively high level of protein sequence polymorphism might be reflected in functional differences at the physiological level in plant developmental processes [46, 47] , but also differential roles as potential bioactive peptides [48] . Thus, we cannot rule out that ␤-conglutin proteins sequence variability may be, at least partially, responsible for differential activities concerning genes transcriptional and proteins translational estimulatory effects in the insulin signaling pathway.
In conclusion, and to the best of our knowledge, this is the first report using this experimental ex vivo system to challenge human blood samples of T2D and C patients with purified NLL conglutin proteins, and in combination with LPS. ␤1, ␤3, and ␤6 triggered increasing expression levels of IRS-1, p85, AKT, and GLUT-4 genes in T2D and C subjects, and attenuated expression levels of IL-1␤ and iNOS, with potential amelioration of the inflammatory state caused by T2D. Furthermore, this study showed for the first time the interaction of recombinant human insulin with various NLL ␤-conglutin proteins, particularly with ␤1, ␤3, and ␤6, which might be a possible mechanism to alter the expression levels of genes in the insulin pathway.
These results highlight the potential use of ␤1-, ␤3-, and ␤6-conglutin proteins as food ingredients and as alternative approaches for T2D prevention, management, and/or treatment. Chronic inflammation is a hallmark of several pathologies, such as T2D rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and cancer. Our work and its future applications can help to develop novel as well as culturally relevant plant-based therapeutic approaches against inflammation attenuation, and at the same time can serve as quality control tools to foster reliable and effective plantbased treatments. Moreover, this methodological approach offers an interesting opportunity to identify potential new bioactive plant peptides and metabolites with anti-diabetic activity, and opens the gate for possible plant-based therapeutic approaches to prevent inflammatory disorders, since the potential role of NLL ␤1, ␤3, and ␤6 having antioxidant and potential anti-inflammatory effects.
Finally, implementation of breeding programs using this experimental knowledge as molecular tools would be helpful in terms of NLL seeds uses in food-derived products with positive human health benefits by producing lupin plants with increased expression and storage of particular ␤-conglutin isoforms with known effects in T2D and related-inflammatory diseases. 
